# Huang Li

> Huang Li is a Series A investor at Cowin Capital backing Biotechnology and Medical Device. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Cowin Capital](https://shizune.co/investors/profile/cowin-capital)
- Total investments: 4
- Last investment: Apr 2024
- Lead investor: 25%
- Last updated: Aug 2026

Huang Li is a Series A investor at Cowin Capital focused on Biotechnology and Medical Device. Money and Banking Nankai University master's and doctoral finance, global CEO Yangtze classes.Cowin founding partner, Nanhai Growth Fund founding partner. Tianjin Private Equity Association sponsors director.Has 10 years of investment banking qualifications, as the first batch of investment bankers, to witness the growth of China'scapital market, a large number of enterprises to provide financial, restructuring and listing, and financing services.With 20 years of professional experience in securities, investment in the investment banking industry has a profound understanding of the industry has a good relationship with them.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 50% |
| Medical Device | 2 | 50% |
| Pharmaceutical | 2 | 50% |
| Biopharma | 1 | 25% |
| Life Science | 1 | 25% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 50% |
| Seed | 1 | 25% |
| Series B | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| AnDiConBio | developer of respiratory anti-infection drugs, offering high-potential, low-risk products like new anti-influenza and oral anti-new coronavirus. | $27.6M | Series A | Apr 29, 2024 |  |
| Cosminde | Cosminde is a developer of gastroenterology soft electronic endoscope products. |  | Series A | Dec 12, 2023 |  |
| Cosminde | Cosminde is a developer of gastroenterology soft electronic endoscope products. |  | Seed | Jan 16, 2023 |  |
| Wellgrow Technology | Wellgrow Technology is a developer of in vitro diagnostic medical equipment and reagents for life sciences, clinical medical diagnostics, and food safety. |  | Series B | Jan 25, 2022 |  |

4 of 4 investments shown.

## Co-investors
- [The National Innovation Center](https://shizune.co/investors/profile/the-national-innovation-center) — VC Fund, 2 deals together
- [BlackRock](https://shizune.co/investors/profile/blackrock) — VC Fund, 1 deal together
- [China Merchants Health](https://shizune.co/investors/profile/china-merchants-health) — VC Fund, 1 deal together
- [Huajin Avenue Investment](https://shizune.co/investors/profile/huajin-avenue-investment) — VC Fund, 1 deal together
- [Huajin Capital](https://shizune.co/investors/profile/huajin-capital) — VC Fund, 1 deal together
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund, 1 deal together

## About Cowin Capital

VC Fund · Shenzhen, China

Cowin Capital is a private placement equity investment company focusing on investing in a pioneering enterprise on a long-term basis. It has 18 years of experience in capital management, whose capital management scale was among the front rank, which invested more than 300 companies, of which 60 more became public companies, and 150 moresuccessfully exit.The company was successfully listed on NEEQ, with code 832793, as the third listed famous domestic venture capital institution in NEEQ. It is committed to supporting the growth of small and medium enterprises, continue to launch high-quality listed companies in China Capital Market.

5 contacts available at Cowin Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Cai Weiliang | Partner | https://shizune.co/investors/profile/cai-weiliang |
| Ding Baoyu | Managing Director, Partner | https://shizune.co/investors/profile/ding-baoyu |
| Dong Dongdong | Partner | https://shizune.co/investors/profile/dong-dongdong |
| Dong Ming | Hangzhou Area Partner | https://shizune.co/investors/profile/dong-ming |
| Huang Li | Founding Partner & CEO | https://shizune.co/investors/profile/huang-li |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Huang Li invest in?

Huang Li invests primarily in Biotechnology, Medical Device and Pharmaceutical startups, most often at Series A and Seed stage. Most of the 4 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Huang Li last invest?

The most recent investment recorded for Huang Li closed in Apr 2024. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co